Literature DB >> 27233154

The contribution of different adipose tissue depots to plasma plasminogen activator inhibitor-1 (PAI-1) levels.

Sunelle A Barnard1, Marlien Pieters2, Zelda De Lange3.   

Abstract

Increased plasma plasminogen activator inhibitor-1 (PAI-1) level is considered a mechanistic pathway through which obesity contributes to increased cardiovascular disease risk. Abdominal adipose tissue specifically, is a major PAI-1 source with visceral adipose tissue (VAT), an ectopic fat depot, generally considered to produce more PAI-1 than subcutaneous adipose tissue. However, this does not necessarily lead to increased plasma PAI-1 levels. This review provides an overview of studies investigating the association between body fat distribution and plasma PAI-1 levels. It discusses factors that influence this relationship and also considers the contribution of other tissue to plasma PAI-1 levels, placing the relative contribution of adipose tissue into perspective. In conclusion, the relationship between VAT and plasma PAI-1 levels is not fixed but can be modulated by a number of factors such as the size of the subcutaneous adipose tissue depot, ethnicity, possibly genetics and other obesity-related metabolic abnormalities.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Body fat distribution; Plasminogen activator inhibitor-1; Subcutaneous adipose tissue; Visceral adipose tissue

Mesh:

Substances:

Year:  2016        PMID: 27233154     DOI: 10.1016/j.blre.2016.05.002

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  13 in total

1.  PAI-1 gain-of-function genotype, factors increasing PAI-1 levels, and airway obstruction: The GALA II Cohort.

Authors:  M G Sherenian; S H Cho; A Levin; J-Y Min; S S Oh; D Hu; J Galanter; S Sen; S Huntsman; C Eng; J R Rodriguez-Santana; D Serebrisky; P C Avila; R Kalhan; L J Smith; L N Borrell; M A Seibold; L Keoki Williams; E G Burchard; R Kumar
Journal:  Clin Exp Allergy       Date:  2017-07-03       Impact factor: 5.018

2.  Plasminogen activator inhibitor-1 gene promoter 4G/5G polymorphism and risks of peripherally inserted central catheter-related venous thrombosis in patients with lung cancer: a prospective cohort study.

Authors:  Yan Fu; Qiufen Xiang; Lingling Xie; Yue Feng; Chunhua Yu; Junying Li
Journal:  Support Care Cancer       Date:  2021-04-24       Impact factor: 3.603

3.  CMKLR1 activation ex vivo does not increase proportionally to serum total chemerin in obese humans.

Authors:  Jay Toulany; Sebastian D Parlee; Christopher J Sinal; Kathryn Slayter; Shelly McNeil; Kerry B Goralski
Journal:  Endocr Connect       Date:  2016-11-08       Impact factor: 3.335

4.  Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function.

Authors:  Benjamin Waschki; Henrik Watz; Olaf Holz; Helgo Magnussen; Beata Olejnicka; Tobias Welte; Klaus F Rabe; Sabina Janciauskiene
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-03-22

5.  Modulation of soluble receptor for advanced glycation end-products (RAGE) isoforms and their ligands in healthy aging.

Authors:  Francesco Scavello; Filippo Zeni; Calogero C Tedesco; Emanuela Mensà; Fabrizio Veglia; Antonio Domenico Procopio; Anna Rita Bonfigli; Fabiola Olivieri; Angela Raucci
Journal:  Aging (Albany NY)       Date:  2019-03-23       Impact factor: 5.682

6.  Immunohistochemical expression of plasminogen activator inhibitor-1 in subcutaneous versus omental adipose tissue in patients after elective abdominal surgery.

Authors:  Mehmet Yildiz; Emine Bozkurtlar; Abdulmunir Azizy; Mehmet Agirbasli
Journal:  Autops Case Rep       Date:  2019-09-30

7.  Plasminogen Activator Inhibitor-1 and Diagnosis of the Metabolic Syndrome in a West African Population.

Authors:  Nuri Kodaman; Melinda C Aldrich; Rafal Sobota; Folkert W Asselbergs; Nancy J Brown; Jason H Moore; Scott M Williams
Journal:  J Am Heart Assoc       Date:  2016-10-03       Impact factor: 5.501

8.  Plasminogen Activator Inhibitor-1 Level Correlates with Lipoprotein Subfractions in Obese Nondiabetic Subjects.

Authors:  Sándor Somodi; Ildikó Seres; Hajnalka Lőrincz; Mariann Harangi; Péter Fülöp; György Paragh
Journal:  Int J Endocrinol       Date:  2018-05-30       Impact factor: 3.257

Review 9.  Therapeutics targeting the fibrinolytic system.

Authors:  Haili Lin; Luning Xu; Shujuan Yu; Wanjin Hong; Mingdong Huang; Peng Xu
Journal:  Exp Mol Med       Date:  2020-03-09       Impact factor: 8.718

Review 10.  Obesity and COVID-19: A jigsaw puzzle with still missing pieces.

Authors:  Konstantinos Michalakis; Grigorios Panagiotou; Ioannis Ilias; Kalliopi Pazaitou-Panayiotou
Journal:  Clin Obes       Date:  2020-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.